Cancer Family
Myomatous Neoplasm
CI-CAN-00000282Explore in graph →
Non-malignant151 active trials1 approved drugs38 evidence items
- NCIt
- C214799
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000282Explore in graph →
Clinical trials
755 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02390843 | Simvastatin With Topotecan and Cyclophosphamide in Relapsed and/or Refractory Pediatric Solid and CNS Tumors(AflacST1402) | completed | Phase 1 | 13 | Emory UniversityOTHER | 1 | Apr 3, 2020 | clinicaltrials |
| NCT01447056 | Most Closely HLA-Matched CTLs for Relapsed Epstein Barr Virus(EBV)-Associated Diseases(MALTED) | completed | Phase 1 | 37 | Baylor College of MedicineOTHER | 1 | Feb 7, 2020 |
| clinicaltrials |
| NCT01962103 | Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors | completed | Phase 1 / Phase 2 | 107 | CelgeneINDUSTRY | 7 | Dec 27, 2019 | clinicaltrials |
| NCT00428272 | HGS-ETR2 to Treat Children With Solid Tumors | terminated | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Dec 17, 2019 | clinicaltrials |
| NCT03411980 | Pharmacokinetics and Safety of Vilaprisan in Renal Impairment | completed | Phase 1 | 26 | BayerINDUSTRY | 1 | Dec 3, 2019 | clinicaltrials |
| NCT00004853 | Comparison of Filgrastim and Filgrastim SD/01in Boosting White Cell Counts After Intensive Chemotherapy | completed | Phase 1 | 34 | National Cancer Institute (NCI)NIH | 1 | Nov 12, 2019 | clinicaltrials |
| NCT02889848 | Safety and Tolerability of Collagenase Clostridium Histolyticum (EN3835) to Treat Uterine Leiomyoma (Fibroids) | completed | Phase 1 | 15 | Advance Biofactures CorporationINDUSTRY | 1 | Jul 10, 2019 | clinicaltrials |
| NCT02409576 | Pilot Study of Expanded , Activated Haploidentical Natural Killer Cell Infusions for Sarcomas(NKEXPSARC) | unknown | Phase 1 / Phase 2 | 20 | National University Hospital, SingaporeOTHER | 1 | Apr 16, 2019 | clinicaltrials |
| NCT02557854 | HIFU Hyperthermia With Liposomal Doxorubicin (DOXIL) for Relapsed or Refractory Pediatric and Young Adult Solid Tumors | withdrawn | Phase 1 | 0 | Theodore LaetschOTHER | 1 | Mar 19, 2019 | clinicaltrials |
| NCT03437070 | Trabectedin, Doxorubicin and Olaratumab in Patients With Metastatic or Recurrent Leiomyosarcoma | withdrawn | Phase 1 | 0 | University of MiamiOTHER | 0 | Mar 18, 2019 | clinicaltrials |
| NCT01154452 | Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma | completed | Phase 1 / Phase 2 | 78 | National Cancer Institute (NCI)NIH | 1 | Aug 15, 2018 | clinicaltrials |
| NCT03111069 | Study of Doxorubicin and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) and Intraoperative Brachytherapy for Unresectable or Refractory Pelvic and Abdominal Rhabdomyosarcoma and Undifferentiated Sarcomas in Children | withdrawn | Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Jul 20, 2018 | clinicaltrials |
| NCT00923351 | Therapy to Treat Ewing's Sarcoma, Rhabdomyosarcoma or Neuroblastoma | completed | Phase 1 / Phase 2 | 44 | National Cancer Institute (NCI)NIH | 1 | Jun 15, 2018 | clinicaltrials |
| NCT00931931 | HSV1716 in Patients With Non-Central Nervous System (Non-CNS) Solid Tumors | completed | Phase 1 | 18 | Timothy CripeOTHER | 1 | Mar 21, 2018 | clinicaltrials |
| NCT01418001 | Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS) | terminated | Phase 1 / Phase 2 | 5 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 11, 2018 | clinicaltrials |
| NCT00944580 | A Vaccine Study for High Risk Cancers | withdrawn | Phase 1 | 0 | Penn State UniversityOTHER | 0 | Nov 24, 2017 | clinicaltrials |
| NCT03092999 | Effect of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of BAY1002670 (Vilaprisan) | completed | Phase 1 | 36 | BayerINDUSTRY | 1 | Aug 18, 2017 | clinicaltrials |
| NCT01241162 | Decitabine Followed by a Cancer Antigen Vaccine for Patients With Neuroblastoma and Sarcoma | completed | Phase 1 | 19 | University of LouisvilleOTHER | 1 | May 9, 2017 | clinicaltrials |
| NCT01125800 | A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB | completed | Phase 1 / Phase 2 | 76 | Novartis PharmaceuticalsINDUSTRY | 6 | Mar 20, 2017 | clinicaltrials |
| NCT00720174 | Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma | completed | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | May 17, 2016 | clinicaltrials |
| NCT01169584 | Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors in Pediatric Patients | completed | Phase 1 | 6 | Jennerex BiotherapeuticsINDUSTRY | 1 | Jan 21, 2016 | clinicaltrials |
| NCT02587169 | Trial of Nilotinib and Adriamycin as Treatment in Liposarcomas and Leiomyosarcomas of Retroperitoneum(GEIS-27) | unknown | Phase 1 / Phase 2 | 40 | Broto, Javier Martín, M.D.INDIV | 1 | Oct 27, 2015 | clinicaltrials |
| NCT00397384 | Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer | completed | Phase 1 | 43 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2015 | clinicaltrials |
| NCT00579475 | The Effect of Mifepristone on Uterine Fibroids and Breast Tissue | completed | Phase 1 | 30 | Karolinska InstitutetOTHER | 1 | May 25, 2015 | clinicaltrials |
| NCT00187174 | Everolimus for Treating Pediatric Patients With Recurrent or Refractory Tumors | completed | Phase 1 | 41 | St. Jude Children's Research HospitalOTHER | 1 | Mar 4, 2015 | clinicaltrials |
| NCT01426633 | Combination Therapy of Gemcitabine and Trabectedin in L-sarcomas | completed | Phase 1 | 5 | Heidelberg UniversityOTHER | 1 | Dec 16, 2014 | clinicaltrials |
| NCT02283502 | Clinical Test of the MRgHIFU System on Uterine Fibroids(MRgHIFU) | unknown | Phase 1 | 20 | Chin-Jung WangOTHER | 1 | Nov 5, 2014 | clinicaltrials |
| NCT02166554 | The Efficacy and Safety Study of a New Cross-linked Hyaluronan Hydrogel in the Reduction of Postsurgical Peritoneal Adhesions(BAP) | completed | Phase 1 / Phase 2 | 216 | BioRegen Biomedical (Changzhou) Co., LtdINDUSTRY | 1 | Jun 18, 2014 | clinicaltrials |
| NCT01816815 | Study in Healthy Tubal Ligated Women to Evaluate Pharmacodynamics, Safety and Pharmacokinetics of BAY1002670 | completed | Phase 1 | 73 | BayerINDUSTRY | 3 | Apr 21, 2014 | clinicaltrials |
| NCT00031681 | 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) | completed | Phase 1 | 41 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2013 | clinicaltrials |
| NCT01697514 | A Study of LY2940680 in Pediatric Medulloblastoma or Rhabdomyosarcoma | withdrawn | Phase 1 | 0 | Eli Lilly and CompanyINDUSTRY | 1 | Aug 27, 2013 | clinicaltrials |
| NCT00012181 | Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas | completed | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2013 | clinicaltrials |
| NCT00077454 | Erlotinib and Temozolomide in Treating Young Patients With Recurrent or Refractory Solid Tumors | completed | Phase 1 | 95 | National Cancer Institute (NCI)NIH | 1 | Jun 5, 2013 | clinicaltrials |
| NCT00101270 | Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas | completed | Phase 1 | 24 | National Cancer Institute (NCI)NIH | 1 | Jun 5, 2013 | clinicaltrials |
| NCT00093821 | Tanespimycin in Treating Young Patients With Recurrent or Refractory Leukemia or Solid Tumors | completed | Phase 1 | 70 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00837161 | Pilot Study of MRI-Guided High Intensity Focused Ultrasound Ablation of Uterine Fibroids | completed | Phase 1 / Phase 2 | 11 | Philips HealthcareINDUSTRY | 1 | Dec 4, 2012 | clinicaltrials |
| NCT00132158 | ZD1839 and Oral Irinotecan in Treating Young Patients With Refractory Solid Tumors | completed | Phase 1 | 19 | St. Jude Children's Research HospitalOTHER | 1 | Apr 17, 2012 | clinicaltrials |
| NCT00436657 | Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Cisplatin for Children With Peritoneal Cancer | completed | Phase 1 | 10 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 2, 2012 | clinicaltrials |
| NCT00361036 | Comparison Study in the Treatment of Uterine Fibroids Uterine Fibroid Embolization Using BeadBlock™ Embolic Agent | completed | Phase 1 | 44 | Worthington-Kirsch, Robert L., M.D.INDIV | 1 | Apr 18, 2011 | clinicaltrials |
| NCT00543790 | Study Evaluating PRA-027 Multiple Ascending Doses In Cycling And Postmenopausal Women | completed | Phase 1 | 48 | Wyeth is now a wholly owned subsidiary of PfizerINDUSTRY | 1 | Oct 28, 2010 | clinicaltrials |
| NCT00444704 | Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PRA-027 Administered to Healthy Japanese Females | completed | Phase 1 | — | Wyeth is now a wholly owned subsidiary of PfizerINDUSTRY | 1 | Jul 10, 2009 | clinicaltrials |
| NCT00574418 | Far Infrared Radiation Treatment for Uterine Fibroids | unknown | Phase 1 | 2 | GAAD Medical Research Institute Inc.OTHER | 1 | Jan 5, 2009 | clinicaltrials |
| NCT00187109 | Recombinant Human Thrombopoietin in Children Receiving Ifosfamide, Carboplatin, and Etoposide Chemotherapy | completed | Phase 1 / Phase 2 | 40 | St. Jude Children's Research HospitalOTHER | 1 | Apr 10, 2008 | clinicaltrials |
| NCT00427544 | Study of the Safety, Tolerability, and PK of PRA-027 Administered to Women of Nonchildbearing Potential | completed | Phase 1 | — | Wyeth is now a wholly owned subsidiary of PfizerINDUSTRY | 1 | Dec 5, 2007 | clinicaltrials |
| NCT00562471 | Safety and Efficacy Study of a Hydrogel, Applied Following Removal of Myomas During Gynecologic Surgery, Administered for the Prevention/Reduction of Postoperative Adhesion Formation | completed | Phase 1 / Phase 2 | 76 | Angiotech PharmaceuticalsINDUSTRY | 3 | Nov 22, 2007 | clinicaltrials |
Data updated 22 days agoSource updated Apr 3, 2020source: clinicaltrials